• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Pharma
Tag:

Pharma

Health

Nine tips to help choose over-the-counter medications safely and wisely – The Irish Times

by Chief Editor April 20, 2026
written by Chief Editor

The Shift Toward Precision Self-Medication

For decades, the pharmacy aisle has been a “one size fits all” experience. You have a headache. you buy paracetamol. You have a cough; you reach for a codeine-based syrup. But the future of over-the-counter (OTC) medicine is moving toward pharmacogenomics—the study of how your genes affect your response to drugs.

Grab codeine as a prime example. As we know, the body converts codeine into morphine to relieve pain. However, not everyone’s liver processes this conversion at the same rate. “Ultra-rapid metabolizers” can experience dangerously high levels of morphine in their system from a standard dose, while “poor metabolizers” get no pain relief at all.

In the coming years, we expect to see a rise in affordable, at-home genetic testing kits. Imagine scanning a QR code on a medication box that cross-references your genetic profile to warn you: “Warning: Your body processes this ingredient too quickly. Consult a pharmacist for a safer alternative.”

Did you know? Some people are genetically unable to perceive the effects of codeine, leading them to accidentally overdose by taking more pills in a desperate attempt to find relief.

Digital Guardians: AI and the End of Medication Errors

The “common sense” approach to OTC safety is often flawed as humans are forgetful. We forget that the “multi-symptom” cold medicine we took this morning already contains paracetamol, and then we take a separate painkiller two hours later, risking liver toxicity.

The next frontier is the AI-integrated medicine cabinet. We are already seeing the emergence of smart apps that allow users to upload photos of their medication labels. These tools don’t just list ingredients; they use semantic AI to predict potential drug-drug interactions in real-time.

Future trends suggest a seamless integration between your wearable health tech (like an Apple Watch or Oura ring) and your OTC usage. If your heart rate is elevated or your blood pressure is spiking, a digital health assistant could warn you against using a pseudoephedrine-based decongestant, which is known to narrow blood vessels and increase blood pressure.

The “Behind-the-Counter” Movement and Stricter Regulation

There is a growing global trend toward reclassifying “low-risk” drugs. The memorandum from the Health Service Executive (HSE) regarding codeine is a harbinger of a larger shift. We are moving away from the “supermarket model” of pharmacy and back toward a “clinical model.”

Expect to see more “Pharmacy-Only” (P) medications—drugs that don’t require a prescription but must be dispensed by a pharmacist after a brief consultation. This prevents the “silent addiction” that occurs when people buy codeine-combination products from various stores to avoid suspicion.

This shift isn’t just about opioids. We are seeing similar scrutiny applied to nasal decongestants. The phenomenon of rhinitis medicamentosa—where the nasal lining becomes dependent on oxymetazoline, leading to permanent tissue damage—is prompting regulators to push for shorter pack sizes and mandatory warning labels regarding the “three-day limit.”

Pro Tip: When shopping for OTCs, always seem for the “active ingredients” list rather than the brand name. Many different brands use the exact same chemical, and buying the generic version often saves you money without sacrificing efficacy.

Beyond the Quick Fix: The Rise of Integrative Alternatives

As public awareness of the risks of long-term OTC use grows, there is a pivot toward integrative pharmacy. Instead of relying on a chemical nasal spray to clear sinuses for a month, patients are being steered toward saline irrigation and corticosteroid sprays which have a lower risk of rebound congestion.

We are also seeing a trend in “precision dosing.” Rather than a standard 500mg tablet, future OTCs may come in customizable delivery systems—such as dissolvable strips or precision-dose liquids—that allow users to take the absolute minimum effective dose, reducing the burden on the liver and kidneys.

For more on managing your health between visits, check out our guide on how to prepare a medication list for your GP to ensure no interaction goes unnoticed.

Frequently Asked Questions

Can I become addicted to OTC codeine?
Yes. Even low-dose codeine can lead to physical and psychological dependence if used for more than three consecutive days. Withdrawal symptoms can include anxiety, insomnia, and restlessness.

Why can’t I use nasal decongestant sprays for a week?
Overuse causes “rebound congestion.” The blood vessels in your nose swell more than before once the drug wears off, making you feel more congested and trapping you in a cycle of dependency.

Are “multi-symptom” medicines better than single-ingredient ones?
Usually, no. They often contain ingredients you don’t need, increasing the risk of side effects and the likelihood of accidentally doubling up on a specific drug (like paracetamol).

Who should I consult before starting a new OTC medication?
Always consult a licensed pharmacist. They are the most accessible healthcare experts and can check for interactions with your existing prescriptions via World Health Organization safety standards.

Join the Conversation

Have you ever experienced a surprising side effect from a common OTC drug, or do you have a tip for staying safe while self-medicating? Share your story in the comments below or subscribe to our newsletter for more evidence-based health insights.

Subscribe for Health Updates

April 20, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Wave Life Sciences: Disappointing Weight Loss Data Triggers Stock Sell-Off

by Chief Editor March 27, 2026
written by Chief Editor

Wave Life Sciences’ Obesity Trial: A Promising Start Tempered by Market Expectations

Wave Life Sciences recently released interim Phase 1 data for its obesity candidate, WVE-007. Whereas the data demonstrates targeted visceral fat reduction, investors reacted with disappointment to the mixed results and modest weight loss. The stock experienced significant selling pressure in a volatile market.

The INLIGHT Study: Focusing on Body Composition

The INLIGHT study centers on a novel approach aimed at reducing fat while simultaneously building muscle mass. In the 240mg dose group, visceral fat decreased by 14.3% after six months, while muscle mass increased by 2.4%. However, overall body weight reduction remained at 0.9%, falling short of market expectations for recent weight loss drugs.

Mixed Results Across Dosage Groups

Data from the 400mg cohort raised further skepticism. Minimal changes in fat and muscle mass were observed after three months. Management attributed this to the better physical condition of participants at the study’s outset, who had approximately 30% less fat reserves than the comparison group.

Analysts Adjust Course

Financial institutions responded decisively. While ratings largely remain positive, price targets have been significantly lowered. Bank of America now sees a fair value of $21.00, while Wells Fargo revised its target to $13.00. Wedbush and Raymond James also reacted with price targets of $15.00 and $12.00, respectively, in response to the new study data.

The Quest for Alternatives to GLP-1 Medications

The biotech sector is closely watching whether alternative approaches can compete with established GLP-1 medications like Wegovy and Zepbound. Wave Life Sciences is focusing on preserving metabolic health through muscle protection, which has yet to translate into substantial weight loss.

Shifting Focus to Higher BMI Patients

The company plans to initiate a Phase 2a study in the second quarter of 2026, targeting patients with a higher Body Mass Index (BMI) between 35 and 50 kg/m². Management anticipates more pronounced metabolic effects and measurable weight loss success within this group.

Financial Stability Supports Future Development

Wave Life Sciences is financially secure for these endeavors. With cash reserves of $602 million, the company’s operational funding is ensured through the third quarter of 2028.

The Future of Obesity Treatment: Beyond Weight Loss

The focus on body composition – specifically, the ratio of visceral fat to muscle mass – represents a potential shift in how obesity is treated. Traditional weight loss metrics often overlook the importance of maintaining lean muscle mass, which is crucial for metabolic health. WVE-007’s ability to potentially achieve this balance could position it uniquely in the market.

The development of WVE-007 also highlights the growing interest in RNA interference (RNAi) therapies for metabolic diseases. RNAi technology offers a precise way to target specific genes involved in disease pathways, potentially leading to more effective and targeted treatments.

Pro Tip:

Understanding the difference between overall weight loss and body composition changes is key when evaluating new obesity treatments. Focus on improvements in metabolic health markers, such as visceral fat reduction and lean muscle mass preservation, rather than solely on the number on the scale.

FAQ

Q: What is WVE-007?
A: WVE-007 is an investigational drug developed by Wave Life Sciences for the treatment of obesity. It uses RNA interference technology to target a specific gene involved in metabolic regulation.

Q: What were the key findings of the Phase 1 INLIGHT trial?
A: The trial showed significant reductions in visceral fat and increases in muscle mass with a 240mg dose of WVE-007, but modest overall weight loss.

Q: What are the next steps for WVE-007?
A: Wave Life Sciences plans to initiate a Phase 2a study in the second quarter of 2026, focusing on patients with a higher BMI (35-50 kg/m²).

Q: Is Wave Life Sciences financially stable?
A: Yes, the company has $602 million in cash reserves, providing funding through the third quarter of 2028.

Did you know? Visceral fat, the fat stored around abdominal organs, is particularly harmful to health and is strongly linked to metabolic diseases like type 2 diabetes and heart disease.

Stay informed about the latest developments in obesity treatment and biotechnology. Explore our other articles for in-depth analysis and expert insights.

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

DiGA Report 2025: 1.7M+ Prescriptions & Growing Adoption of Digital Health Apps in Germany

by Chief Editor March 27, 2026
written by Chief Editor

Digital Health in Germany: A Million Strong and Growing

Germany is rapidly becoming a leader in digital healthcare, with the number of patients utilizing Digital Health Applications (DiGA) exceeding 1.7 million. The latest report from the Spitzenverband Digitale Gesundheitsversorgung (SVDGV) reveals a 64% growth rate in DiGA usage in 2025 alone, signaling a significant shift in how healthcare is delivered and accessed.

What are DiGAs?

DiGAs are apps or web-based applications designed to support the detection, monitoring, treatment, or alleviation of illnesses and disabilities. Crucially, these aren’t just any health apps; they are certified medical devices, rigorously vetted by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and often covered by statutory health insurance.

A Growing Ecosystem: From 58 to 78 DiGAs

As of December 31, 2025, 58 DiGAs were listed in the BfArM directory, with 48 receiving permanent approval. This number has already grown to 78 as of March 27, 2026, offering a wider range of options for physicians to prescribe and patients to utilize. This expansion demonstrates the increasing confidence in digital health solutions.

Addressing Healthcare Challenges with Digital Solutions

The rise of DiGAs comes at a critical time for Germany’s healthcare system. Facing a shortage of medical professionals and increasing strain on existing infrastructure, DiGAs offer a scalable and accessible solution to bridge care gaps. They provide patients with timely access to evidence-based therapies, regardless of location or time constraints.

The Role of DiGAs in a Strained System

Dr. Anna Haas, a representative of the SVDGV, emphasizes that DiGAs are “here to stay.” Their ability to deliver care remotely and efficiently makes them invaluable in a system grappling with resource limitations. This is particularly relevant for managing chronic conditions and providing preventative care.

Future Trends and Regulatory Hurdles

While the growth of DiGAs is promising, the SVDGV highlights the require for supportive regulatory frameworks to ensure continued innovation and adoption. Key areas for improvement include:

Harmonization Across Europe

Creating uniform standards for DiGA reimbursement across Europe would foster a more consistent and accessible digital health market. This would allow for greater scalability and cross-border collaboration.

Simplifying Patient Access

Streamlining the process for patients to access DiGAs, potentially through the implementation of a practical e-prescription system, is crucial. Reducing administrative burdens will encourage wider adoption.

Reducing Bureaucracy

The SVDGV advocates for a reduction in bureaucratic hurdles for DiGA developers, allowing them to focus on innovation and improving patient care. This includes simplifying the approval process and reducing reporting requirements.

Recent Updates to DiGA Regulations

The Second Ordinance amending the Digital Health Applications Regulation came into effect on February 1, 2026. This update focuses on refining the application-accompanying success measurement (AbEM) and adjusting the categorization of change notifications. The application forms in the DiGA portal have been updated, including price reporting, which now must be submitted through the portal.

Changes to ePA Integration and GesundheitsID

The process for verifying the requirements for writing DiGAs into the electronic patient record (ePA) and implementing the GesundheitsID has been updated. Developers are now required to submit a self-declaration.

FAQ

What is the BfArM? The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the German Federal Institute for Drugs and Medical Devices, responsible for approving and overseeing DiGAs.

Are DiGAs covered by insurance? Generally, yes. DiGAs listed in the BfArM directory are often covered by statutory health insurance.

What is the DiGA-Report? The DiGA-Report is an annual report published by the SVDGV, providing data and insights into the usage and development of DiGAs in Germany.

What is the GesundheitsID? The GesundheitsID is a digital health identity used to securely access and share health data.

Did you know? Patient use of DiGAs has surpassed 1.7 million since their introduction into the German healthcare system in 2020.

Pro Tip: Stay informed about the latest DiGA regulations and updates by regularly visiting the BfArM website.

Explore more about the future of digital health and its impact on patient care. Share your thoughts in the comments below!

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Eli Lilly’s Zepbound: New Employer Program to Boost Access & Sales

by Chief Editor March 7, 2026
written by Chief Editor

Eli Lilly’s Employer Connect: A New Prescription for Obesity Care Access?

Eli Lilly is tackling a critical barrier to widespread obesity treatment: access. The pharmaceutical giant has launched “Employer Connect,” a platform designed to bridge the gap between patients, employers, and independent program administrators, aiming to make medications like Zepbound more readily available to U.S. Workers.

The Challenge of Affordability and Coverage

Despite growing medical demand, a significant hurdle remains: cost and inconsistent insurance coverage. Lilly estimates that roughly half of individuals with commercial insurance face difficulties initiating or continuing obesity medication treatment. This lack of access isn’t just a patient issue; it’s a business impediment for Lilly, limiting the potential market for its drugs.

How Employer Connect Works

The Employer Connect platform facilitates direct connections between employers and over 15 independent program administrators. These administrators can then develop tailored, transparent solutions for employees seeking obesity care. A key feature is the offering of Zepbound (tirzepatide) at a list price of $449 per month for all dosages, without traditional rebates. This aims to provide employers with greater cost predictability.

Employers can choose from administrators offering basic services like enrollment and claims processing, or more comprehensive programs including telemedicine, nutritional guidance, and lifestyle support. Currently, approximately 20% of companies with over 200 employees cover GLP-1 medications for weight loss, rising to 43% for larger employers (5,000+ employees).

A Shift in Industry Approach

Experts view Employer Connect as an incremental but significant step. Previously, manufacturers and pharmacy benefit managers often opposed external discount programs. Now, GLP-1 providers are increasingly collaborating with these models to expand access. This represents a notable change in strategy.

Pro Tip: The move towards direct-to-employer platforms could reshape negotiations between pharmaceutical companies and pharmacy benefit managers, potentially leading to more transparent pricing structures.

Lilly’s Financial Momentum and Future Pipeline

Lilly’s financial performance is currently bolstered by its incretin products. In 2025, the company reported $65.2 billion in revenue (+45%) and earnings per share of $24.21 (+86%). Mounjaro and Zepbound drove much of this growth, increasing by 99% and 175% respectively.

However, this success also creates a concentration risk. Currently, these two GLP-1 products account for 56% of Lilly’s total revenue. The company is actively diversifying its pipeline with oral GLP-1 options like orforglipron, which is awaiting FDA approval, and retatrutide, currently in Phase 3 trials.

Looking Ahead: Orforglipron and Beyond

The FDA decision on orforglipron, expected in the second quarter of 2026, is a key catalyst for Lilly. International launches are planned for 2027. Phase 3 data for retatrutide will also be closely watched, as Lilly seeks to demonstrate its ability to sustain growth beyond its current GLP-1 offerings.

Lilly’s stock has experienced recent downward pressure (-4.24% in the last week). Investors will be looking for positive developments regarding orforglipron and retatrutide to reaffirm confidence in the company’s long-term growth prospects.

Frequently Asked Questions

Q: What is Zepbound?
A: Zepbound (tirzepatide) is a medication developed by Eli Lilly for weight management.

Q: What does Employer Connect aim to achieve?
A: Employer Connect seeks to improve access to obesity medications like Zepbound by connecting employers with program administrators offering affordable and comprehensive care solutions.

Q: How does the $449 price point for Zepbound work?
A: The $449 price is a list price offered through the platform, and importantly, excludes traditional rebates, providing employers with greater cost transparency.

Q: What is orforglipron?
A: Orforglipron is an oral GLP-1 medication in development by Eli Lilly, awaiting FDA approval.

Did you know? The launch of Employer Connect follows a trend of pharmaceutical companies exploring direct-to-employer models to bypass traditional pharmacy benefit managers and improve drug access.

What are your thoughts on Eli Lilly’s new platform? Share your comments below!

March 7, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

What Big Pharma Won’t Tell You: The Ancient Natural Remedy People Swear By — and It Costs Almost Nothing

by Chief Editor March 1, 2026
written by Chief Editor

The Enduring Allure of Natural Medicine: Navigating the Future of Healing

Claims about suppressed natural remedies and “Big Pharma” conspiracies are widespread online. The narrative is compelling – an ancient solution, overlooked in favor of profit. But the reality is far more complex, a blend of historical precedent, scientific rigor, and evolving consumer expectations.

From Ancient Roots to Modern Science

Throughout history, communities have relied on natural preparations to address health concerns. Many modern pharmaceuticals originated from compounds first identified in nature. Willow bark, containing salicin, led to aspirin. Artemisinin, derived from sweet wormwood, is now a key malaria treatment. These examples demonstrate the potential of traditional remedies to inform modern medicine.

“Natural substances are often the starting point of pharmaceutical innovation,” note pharmacology researchers.

But, the critical difference lies in testing, standardization, and dosing. Simply being “natural” doesn’t guarantee effectiveness or safety.

Why the Appeal? Trust, Transparency, and the Search for Alternatives

The pharmaceutical industry faces scrutiny regarding pricing and patents, fueling suspicion that inexpensive natural solutions are ignored. Although some herbal products are legally sold and even supported by evidence, the issue isn’t about natural versus synthetic – it’s about rigorous evaluation. If a natural compound demonstrates clinical benefits, it can be studied and commercialized.

This growing interest in natural approaches similarly reflects a broader desire for more holistic and preventative healthcare. Consumers are increasingly seeking greater control over their health and wellness, and are often drawn to remedies perceived as gentler or less invasive than conventional treatments.

What Natural Remedies Show Promise?

Certain natural interventions demonstrate evidence for specific uses. Honey can provide mild cough relief. Ginger is effective for nausea. Turmeric compounds may offer inflammatory support, though evidence varies. Peppermint oil can alleviate certain digestive symptoms. However, “works” doesn’t equate to a universal cure, and effectiveness depends on dosage, formulation, and individual context.

Pro Tip: Always discuss any natural remedies with your healthcare provider, especially if you are taking prescription medications, to avoid potential interactions.

The Challenge of “One-Size-Fits-All” Claims

The idea of a single ancient remedy treating a wide range of modern diseases is scientifically improbable. Human biology is complex, and diseases vary in cause and progression. Even natural substances can carry risks, side effects, or interact with medications. “Natural” doesn’t automatically imply “safe.”

The Future of Validation: Rigor and Research

For a treatment – natural or synthetic – to be considered reliable, it requires:

  • Controlled clinical trials
  • Safety evaluations
  • Standardized dosing studies
  • Peer-reviewed publication

Without these steps, claims remain anecdotal. The future of natural medicine lies in bridging the gap between traditional knowledge and modern scientific methodology.

Emerging Trends: Personalized Natural Medicine & Traditional Knowledge Integration

Several trends are shaping the future of natural medicine:

  • Personalized Natural Medicine: Advances in genomics and metabolomics are enabling a more personalized approach to natural therapies, tailoring treatments to an individual’s unique biological makeup.
  • Integration with Conventional Medicine: Increasingly, healthcare systems are exploring integrative approaches, combining conventional treatments with complementary therapies like acupuncture, herbal medicine, and naturopathy. The WHO recognizes the importance of traditional medicine, with 170 Member States reporting its use.
  • Revival of Ancient Practices: There’s renewed interest in ancient healing systems like Ayurveda and Traditional Chinese Medicine, driven by a desire for holistic approaches to health.
  • Focus on Preventative Care: Natural medicine emphasizes preventative care through diet, lifestyle, and stress management, aligning with a growing focus on wellness and proactive health management.

FAQ: Natural Medicine in the 21st Century

Q: Are natural remedies always safe?
A: No. “Natural” doesn’t automatically mean safe. Natural substances can have side effects and interact with medications.

Q: Can natural remedies replace conventional medicine?
A: Not typically. Natural remedies can be used as complementary therapies, but should not replace conventional medical care without consulting a healthcare professional.

Q: How can I find reliable information about natural remedies?
A: Appear for information from reputable sources, such as peer-reviewed scientific studies, and consult with qualified healthcare practitioners.

Q: Is “Big Pharma” suppressing natural cures?
A: While concerns about pharmaceutical industry practices are valid, the idea of a deliberate suppression of effective natural remedies is largely unsubstantiated. The focus should be on rigorous scientific evaluation.

Skepticism toward sensational claims isn’t cynicism – it’s critical thinking. When it comes to health, decisions are best guided by transparent evidence and professional medical advice.

Did you know? Approximately 40% of pharmaceutical products today draw from nature and traditional knowledge, including drugs like aspirin and artemisinin.

Explore Further: Learn more about the role of traditional medicine from the World Health Organization.

Join the Conversation: What are your thoughts on the future of natural medicine? Share your experiences and insights in the comments below!

March 1, 2026 0 comments
0 FacebookTwitterPinterestEmail
Business

Nervousness pervades the Irish jobs market. Normal slippage, or something else? – The Irish Times

by Chief Editor January 30, 2026
written by Chief Editor

Ireland’s Job Market: Navigating Uncertainty and the Rise of AI

For years, Ireland’s employment figures defied global headwinds. From the tail end of the Covid-19 pandemic through much of 2024, the unemployment rate remained remarkably stable, hovering between 4% and 4.5% – a level often considered full employment. This resilience, touted by the government, seemed to withstand the shocks of the Ukraine war, soaring inflation, and shifting global trade dynamics. However, that stability is now showing cracks. A recent uptick to 5% overall, with youth unemployment climbing to 14%, is fueling anxieties about the future.

The Shifting Sands of Employment Growth

While Enterprise Ireland reports continued job growth among its client companies – over 12,000 new positions in the past year – the pace is slowing. The surge of over 20,000 jobs in 2021, a post-pandemic bounce, hasn’t been replicated. Experts like Kevin Sherry of Enterprise Ireland acknowledge a cautious approach to hiring, influenced by factors like US tariffs and ongoing geopolitical uncertainty. The key takeaway isn’t necessarily job losses, but a deceleration in the rate of new job creation.

“We don’t want to see big peaks and troughs… Importantly, the job losses number has not increased.” – Kevin Sherry, Enterprise Ireland Executive Director

Amazon and the AI Factor: A White-Collar Wake-Up Call

Recent announcements, like Amazon’s global cuts impacting potentially 300 Irish roles, are amplifying these concerns. These aren’t blue-collar layoffs; they’re impacting white-collar workers – professionals with established careers facing a suddenly more competitive landscape. Amazon, like many tech giants, is streamlining operations and leveraging advancements in artificial intelligence to reduce headcount. This trend signals a broader shift in the types of skills in demand.

The Multinational Slowdown and Sectoral Divergence

Economists at Bank of Ireland and the Economic and Social Research Institute (ESRI) predict a further cooling of employment growth, forecasting a rate of just 1.5% for 2026. Conall Mac Coille, chief economist at Bank of Ireland, believes the era of rapid expansion in the multinational sector is over. Companies like Google and Meta, which aggressively hired during the pandemic, are now recalibrating their workforces.

However, the picture isn’t uniformly bleak. Manufacturing, construction, and the public sector are showing resilience. Increased government spending on wages is bolstering the public sector, while manufacturing benefits from ongoing demand. Consumer-facing businesses, particularly restaurants, are struggling with rising energy costs and food price inflation, contributing to the rise in youth unemployment and a decline in part-time work.

Skills Gaps and the Future of Work

A persistent skills gap remains a significant challenge. Christopher Paye of StepStone Group Ireland highlights that nearly 70% of employers struggle to find talent equipped to “future-proof” their operations. This isn’t just about technical skills like AI and data analysis; employers are increasingly prioritizing “soft skills” – leadership, people management, and adaptability.

The rise of AI is reshaping career trajectories. Repetitive tasks are being automated, creating a need for graduates to be more flexible and open to new roles. Universities are responding by collaborating with industry to ensure their curricula align with evolving employer needs. Demand is growing in areas like data compliance, reflecting the increasing importance of data privacy and security.

“Our message to graduates is to be more open-minded… There are fewer visible roles, but interesting opportunities exist for those who adapt.” – Trayc Keevans, Global FDI Director, Morgan McKinley

Diversification of Investment and Emerging Opportunities

While the US remains a crucial source of foreign direct investment (FDI), Ireland is seeing increased interest from other regions, particularly China. Chinese companies are exploring opportunities in technology, pharmaceuticals, and other sectors, often through mergers and acquisitions. This diversification is a positive sign, reducing Ireland’s reliance on a single market.

Navigating the New Normal: A Focus on Control

The overall outlook suggests a period of slower, more sustainable growth. The key for Irish businesses, as Kevin Sherry of Enterprise Ireland advises, is to focus on “controlling the controllables” – managing internal operations effectively and adapting to the external environment.

FAQ: Ireland’s Job Market in 2026

  • What is the current unemployment rate in Ireland? Approximately 5%, with youth unemployment at 14%.
  • Is Ireland heading for a recession? While growth is slowing, economists don’t currently predict an immediate recession.
  • What skills are most in demand? AI, data analysis, data compliance, leadership, and people management.
  • How is AI impacting the job market? AI is automating repetitive tasks, leading to a shift in the types of skills employers seek.
  • What sectors are performing well? Manufacturing, construction, and the public sector.

Pro Tip: Invest in upskilling and reskilling programs to stay ahead of the curve. Focus on developing both technical and soft skills to enhance your employability.

Did you know? Ireland’s IDA attracted a record level of foreign investment in 2024, despite global economic challenges.

Want to learn more about navigating the changing job market? Explore our career resources or subscribe to our newsletter for the latest insights.

January 30, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Ozempic & Wegovy: Weight Regain After Stopping GLP-1 Drugs

by Chief Editor January 8, 2026
written by Chief Editor

The Ozempic Effect: Why Weight Loss Drugs May Be a Lifelong Commitment

The buzz around GLP-1 receptor agonists like Ozempic and Wegovy has been deafening. Initially designed for managing Type 2 diabetes, these medications have become synonymous with rapid weight loss. But a recent study from the University of Oxford, analyzing 37 clinical trials, reveals a crucial caveat: the weight often returns once the drugs are stopped. This isn’t a quick fix; it’s potentially a long-term management strategy, and understanding the implications is vital.

The Rebound Effect: What the Data Shows

The Oxford study found that individuals regain, on average, approximately 0.4 kilograms (0.88 pounds) per month after discontinuing GLP-1 medications. Specifically, those taking drugs like Ozempic, Wegovy, Mounjaro, and Zepbound lost an average of 15 kilograms (33 pounds) during treatment, only to regain 10 kilograms (22 pounds) within a year. Researchers predict a return to original weight within 18 months, accompanied by a reversal of positive metabolic changes like improved blood pressure and cholesterol levels. This echoes findings from a 2023 study published in The New England Journal of Medicine, which demonstrated significant weight regain after stopping semaglutide (Ozempic/Wegovy).

This rebound isn’t unique to medication. Traditional diet and exercise programs also see weight regain, but the pace is slower – typically taking around four years to revert to the starting weight. “A larger weight loss tends to lead to a faster weight regain,” explains Sam West, the study’s lead researcher. “But weight regain after medication is consistently faster, regardless of how much weight was initially lost.”

Why Does Weight Return? The Biological Factors

The core issue lies in how these drugs work. GLP-1 agonists mimic a natural hormone that regulates appetite and blood sugar. They increase feelings of fullness and reduce cravings. When stopped, these effects diminish, and the body often reverts to its previous set point. Furthermore, research suggests that GLP-1 medications may alter gut microbiome composition, and these changes could contribute to weight regain after discontinuation. Recent studies are exploring the complex interplay between GLP-1 agonists and the gut microbiome, aiming to understand how to mitigate this effect.

Did you know? Your body has a ‘set point’ weight it naturally defends. GLP-1 drugs temporarily lower this set point, but stopping the medication can cause it to rebound.

The Cost Factor and Access Issues

Beyond the biological challenges, the financial burden is significant. In the US, these medications can cost over $1,000 per month, making long-term use unsustainable for many. Insurance coverage varies widely, and access remains a major barrier. This creates a scenario where individuals may cycle on and off the medication, potentially exacerbating the rebound effect. The high cost also fuels a black market for counterfeit drugs, posing serious health risks.

The Future of Weight Management: Combination Therapies and Personalized Approaches

The Oxford study underscores that GLP-1 medications are a powerful tool, but not a cure. The future of weight management likely lies in a multi-faceted approach. Here’s what we can expect:

  • Combination Therapies: Combining GLP-1 agonists with behavioral interventions – dietary counseling, exercise programs, and psychological support – is crucial for long-term success.
  • Personalized Medicine: Genetic testing and microbiome analysis could help identify individuals who are most likely to benefit from these medications and those who may experience more significant rebound effects.
  • New Drug Development: Pharmaceutical companies are actively researching next-generation GLP-1 agonists with potentially longer-lasting effects and fewer side effects. Dual-agonist drugs, targeting both GLP-1 and GIP receptors, are showing promising results in clinical trials.
  • Focus on Lifestyle Integration: The emphasis will shift towards using medication as a bridge to adopt and maintain healthy lifestyle habits.

Pro Tip: Don’t view GLP-1 medications as a standalone solution. Prioritize working with a registered dietitian and a certified personal trainer to build sustainable healthy habits.

The Role of Digital Health and Remote Monitoring

Digital health technologies, such as wearable sensors and mobile apps, will play an increasingly important role in monitoring weight, activity levels, and dietary intake. Remote patient monitoring allows healthcare providers to track progress, provide personalized feedback, and adjust treatment plans as needed. This proactive approach can help prevent or minimize weight regain.

FAQ

  • Q: Will I definitely regain weight if I stop Ozempic/Wegovy?
    A: The study shows a high likelihood of weight regain, but the amount varies. Lifestyle factors play a significant role.
  • Q: How long do I need to take these medications?
    A: Currently, the data suggests potentially lifelong use to maintain weight loss.
  • Q: Are there any alternatives to medication?
    A: Diet and exercise are effective, but often result in slower weight loss. Bariatric surgery is another option for individuals with severe obesity.
  • Q: What are the common side effects of GLP-1 medications?
    A: Nausea, vomiting, diarrhea, and constipation are common. More serious, though rare, side effects have been reported.

The era of “magic bullet” weight loss solutions is over. GLP-1 medications offer a significant advancement, but they are most effective when integrated into a comprehensive, long-term strategy that prioritizes lifestyle changes and personalized care.

Reader Question: “I’m worried about the cost of continuing Wegovy long-term. Are there any patient assistance programs available?” (Share your experiences and resources in the comments below!)

Explore further: Read our article on The Gut Microbiome and Weight Loss for a deeper dive into the science behind metabolic health.

Stay informed! Subscribe to our newsletter for the latest updates on weight management and metabolic health.

January 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Darmstadt: Severe Attack on Doctor – Hospital Demands Action Against Violence

by Chief Editor December 19, 2025
written by Chief Editor

Rising Tides of Violence: Protecting Healthcare Workers in a Changing World

A recent, brutal attack on a physician at the Klinikum Darmstadt in Germany – requiring intensive care – is a stark reminder of a growing global crisis: violence against healthcare workers. This isn’t an isolated incident. From emergency rooms to general practice, doctors, nurses, and support staff are increasingly facing verbal abuse, threats, and physical assaults. The question isn’t *if* things will escalate, but *how* healthcare systems will adapt to protect their personnel and ensure continued patient care.

The Escalating Threat: Beyond Disrespect

As highlighted by the Klinikum Darmstadt and the Kassenärztliche Vereinigung Hessen (KVH), the nature of these attacks is shifting. It’s no longer simply a matter of lacking respect; it’s “raw violence,” as KVH leaders stated. This escalation is fueled by a complex interplay of factors. Increased patient anxiety and frustration, often exacerbated by long wait times and strained resources, play a significant role. The COVID-19 pandemic, with its associated stress and misinformation, demonstrably worsened the situation. A 2022 survey by the American College of Emergency Physicians found that 88% of emergency physicians reported experiencing workplace violence.

Furthermore, societal trends like increasing mental health challenges and a decline in civility contribute to the problem. The normalization of aggressive behavior in public discourse seems to be bleeding into healthcare settings.

Security Measures: From Bodycams to Dedicated Protection

Healthcare facilities are responding with a range of security measures. The Klinikum Dortmund, for example, is piloting the use of bodycams, a strategy gaining traction in several countries. These cameras aim to deter aggression, provide evidence in case of incidents, and offer a sense of security to staff. However, bodycams are not a panacea. Concerns about privacy, data storage, and potential escalation of conflict need careful consideration.

Beyond technology, there’s a growing call for dedicated security personnel, particularly in high-risk areas like emergency departments and urgent care centers. The Klinikum Darmstadt and KVH rightly point out that “security doesn’t come for free,” and adequate funding is crucial. This requires a shift in perspective – viewing security not as an optional expense, but as a fundamental component of healthcare infrastructure.

Pro Tip: De-escalation training for all healthcare staff is a cost-effective and valuable investment. Equipping personnel with the skills to recognize and manage potentially volatile situations can prevent escalation and protect both staff and patients.

The Role of Technology and AI in Predictive Security

Looking ahead, technology will play an increasingly sophisticated role in healthcare security. Artificial intelligence (AI) and machine learning algorithms can analyze data – patient history, behavioral patterns, even social media activity – to identify individuals at higher risk of exhibiting aggressive behavior. This allows for proactive interventions, such as increased staff presence or pre-emptive counseling.

Real-time location systems (RTLS) can track staff movements, enabling rapid response to emergencies. Smart sensors can detect unusual sounds or movements, triggering alerts. However, the ethical implications of using AI for predictive policing in healthcare must be carefully addressed. Transparency, fairness, and data privacy are paramount.

Addressing the Root Causes: A Holistic Approach

While security measures are essential, they address the symptoms, not the underlying causes. A truly effective solution requires a holistic approach that tackles the root of the problem. This includes:

  • Improved Mental Health Support: Increased access to mental healthcare for both patients and healthcare workers.
  • Public Awareness Campaigns: Educating the public about the importance of respecting healthcare professionals.
  • Addressing Systemic Issues: Reducing wait times, improving communication, and addressing resource shortages.
  • Legal Protections: Strengthening legal frameworks to deter violence against healthcare workers and ensure swift prosecution of offenders.

The UK’s National Health Service (NHS) is implementing a “zero tolerance” policy towards violence and aggression, coupled with increased training and support for staff. This demonstrates a commitment to creating a safer working environment.

FAQ: Violence Against Healthcare Workers

  • Q: Is violence against healthcare workers increasing? A: Yes, data from multiple countries indicates a significant and concerning rise in incidents.
  • Q: What are the most common types of violence? A: Verbal abuse is the most frequent, followed by threats and physical assault.
  • Q: What can patients do to help? A: Treat healthcare workers with respect, be patient, and communicate your concerns calmly.
  • Q: Are there legal consequences for assaulting a healthcare worker? A: Yes, most jurisdictions have laws that impose stricter penalties for assaulting individuals providing essential services.

Did you know? Nurses are disproportionately affected by workplace violence, with studies showing they are significantly more likely to experience physical assault than other healthcare professionals.

The attack at Klinikum Darmstadt serves as a wake-up call. Protecting healthcare workers is not just a matter of ensuring their safety; it’s about safeguarding the entire healthcare system. Without a safe and supported workforce, access to quality care will be compromised. The time for decisive action is now.

Explore more articles on Klinik News and Healthcare Management.

Share your thoughts on this critical issue in the comments below!

December 19, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Eli Lilly’s Orforglipron: Weight Loss Pill Shows 12.4% Loss & FDA Decision Nears

by Chief Editor December 19, 2025
written by Chief Editor

Eli Lilly’s Orforglipron: A Pill Poised to Reshape the Weight Loss Market

The race to combat obesity is heating up, and Eli Lilly just threw a significant contender into the ring. Recent Phase 3 trial results for Orforglipron, an oral weight loss medication, are generating considerable buzz – and a positive reaction from investors. This isn’t just another diet pill; it represents a potential shift in how we approach weight management, offering a convenient alternative to currently available injectable medications.

The Promise of a Pill: Convenience Drives Adoption

For many, the biggest barrier to entry with medications like Wegovy and Zepbound isn’t necessarily the cost or side effects, but the administration method. Daily injections aren’t for everyone. Orforglipron, taken as a once-daily pill, sidesteps this issue. Clinical trial data demonstrates its effectiveness: patients switching from Wegovy experienced minimal weight regain (just 0.9 kg difference over 52 weeks), while those transitioning from Zepbound fared even better (a 5.0 kg difference). Crucially, the study showed an average weight loss of 12.4% over the course of a year.

This convenience factor is predicted to significantly broaden the appeal of weight loss medications. A recent survey by Ipsos revealed that 62% of adults who are interested in weight loss medication would prefer a pill over an injection, citing ease of use and reduced anxiety as primary reasons.

FDA Approval and Market Dynamics

Eli Lilly has already submitted Orforglipron for FDA approval, with a decision expected by the end of March. Approval would position Lilly to directly compete with Novo Nordisk, the current market leader with Wegovy and Ozempic. The obesity treatment market is projected to reach over $100 billion by 2033, making it a fiercely contested space.

However, the landscape isn’t without its challenges. The Medicare price negotiations, impacting drugs like Lilly’s Jardiance, highlight the increasing pressure on pharmaceutical pricing. While seven of the ten drugs subject to negotiation are expected to fall below $100/month, this trend signals a broader shift towards cost containment in the healthcare sector.

Beyond Orforglipron: The Future of Obesity Treatment

Orforglipron isn’t an isolated development. Several other oral weight loss medications are in development, suggesting a future where patients have a wider range of options tailored to their individual needs and preferences. Research is also focusing on combination therapies – pairing medications with lifestyle interventions like diet and exercise – to maximize effectiveness and long-term maintenance.

Did you know? Obesity is a chronic disease affecting over 40% of adults in the United States, according to the Centers for Disease Control and Prevention. Effective treatment options are crucial for improving public health outcomes.

The Role of GLP-1 Receptor Agonists

Orforglipron, like Wegovy and Zepbound, is a GLP-1 receptor agonist. These medications work by mimicking the effects of a natural hormone that regulates appetite and blood sugar levels. They’ve demonstrated remarkable efficacy in promoting weight loss, but also come with potential side effects, such as nausea and gastrointestinal discomfort. Ongoing research aims to refine these medications to minimize side effects and enhance their therapeutic benefits.

Pro Tip: Weight loss medications are most effective when combined with a healthy diet and regular physical activity. They are tools to support lifestyle changes, not replacements for them.

Investor Reaction and Stock Performance

The positive trial results for Orforglipron have already been reflected in Eli Lilly’s stock price, which saw a pre-market boost. This demonstrates investor confidence in the drug’s potential to drive future revenue growth. However, it’s important to remember that stock market performance is influenced by a multitude of factors, and past performance is not indicative of future results.

Frequently Asked Questions (FAQ)

  • What is Orforglipron? A once-daily oral medication for weight loss developed by Eli Lilly.
  • How effective is Orforglipron? Clinical trials showed an average weight loss of 12.4% over 52 weeks.
  • When will Orforglipron be available? Pending FDA approval, a decision is expected by the end of March.
  • Is Orforglipron right for me? Consult with your doctor to determine if Orforglipron is a suitable treatment option based on your individual health profile.
  • What are the potential side effects? Common side effects may include nausea and gastrointestinal discomfort.

Reader Question: “I’m concerned about the long-term effects of these medications. What research is being done to address this?” – Sarah M., California. Pharmaceutical companies are conducting ongoing studies to assess the long-term safety and efficacy of GLP-1 receptor agonists. Researchers are also investigating potential biomarkers to identify individuals who are most likely to benefit from these medications and experience minimal side effects.

The development of Orforglipron marks a significant step forward in the fight against obesity. By offering a convenient and effective oral treatment option, Eli Lilly is poised to reshape the weight loss market and empower individuals to take control of their health. The coming months will be crucial as we await the FDA’s decision and observe how this new medication impacts the broader healthcare landscape.

Want to learn more about the latest advancements in obesity treatment and pharmaceutical innovation? Explore our healthcare innovation section for in-depth articles and expert analysis.

December 19, 2025 0 comments
0 FacebookTwitterPinterestEmail
World

Irish exporters ‘told to shut their mouths’ over Trump tariffs – The Irish Times

by Chief Editor August 8, 2025
written by Chief Editor

“Loose Lips Sink Ships” in the Trade Wars: Navigating Uncertainty in a Changing Global Landscape

The echoes of wartime propaganda, “Loose lips sink ships,” resonate in today’s complex trade environment. This advice, once meant to protect national security, now applies to businesses and organizations grappling with shifting tariffs and unpredictable trade policies. The recent trade agreements between the European Union and the United States highlight this, with businesses in Ireland, particularly within the dairy and pharmaceutical industries, finding themselves in a state of cautious silence.

The Murky Waters of Trade Agreements: Tariffs and Their Impact

The core issue driving this nervousness is the implementation of tariffs. The recent 15% tariff, for example, has cast a long shadow. While the framework agreement aims to provide clarity, the situation remains fluid. Businesses are hesitant to comment, fearful of saying the wrong thing and drawing unwanted attention.

The Dairy Industry’s Dilemma: Kerrygold and Beyond

The dairy industry, a major player in Irish exports, faces significant challenges. The fluctuating tariff rates, particularly for products like Kerrygold butter, have created uncertainty. During the former presidency, tariffs soared to 25% due to the Boeing/Airbus dispute, adding to existing rates. A subsequent reduction to 16% provided some relief, but the return of higher tariffs has, once again, left businesses scrambling.

The current 15% rate, while seemingly a “ceiling,” still leaves room for concern. One industry expert mentioned that “Trump could still tear it all up” which could dramatically alter the situation. The expert continued, “People are being told to shut their mouths and say nothing.”

We’re glad to see the president insist that things need to change and are hopeful that the reciprocal framework process will yield meaningful policy shifts by the EU

— Shawna Morris of the National Milk Producers Federation in the US

Did you know? Kerrygold is the second-largest butter brand in the US market, illustrating the high stakes involved in these tariff disputes.

The Beef Sector and Beyond: Winners and Losers in the Trade Game

While the dairy sector feels the most pressure, other sectors, like beef, may find themselves with unexpected advantages. One importer, Justin Marx of Marx Foods, suggested that the current framework could benefit the Irish beef sector. With tariffs on Brazilian beef at 50%, Irish beef has a competitive edge with a 15% tariff. However, this advantage is fragile and subject to constant change.

The Pharmaceutical Industry: A New Battlefield

The pharmaceutical industry is bracing for impact. Recent statements suggest potential increases in tariffs, which could rise as high as 250% on certain products. This uncertainty makes long-term planning difficult and requires careful risk assessment.

Pro Tip: Businesses should closely monitor policy changes and diversify their supply chains to mitigate risks associated with trade volatility.

The Future: Navigating the Uncertainty

The current trade environment is characterized by volatility and unpredictability. Businesses must adapt to this new reality. The changing geopolitical landscape is forcing companies to make decisions with imperfect information, a stark contrast to the more stable free trade era.

Semiconductor Tariffs

The situation is further complicated by proposed tariffs on semiconductors. While exemptions are possible for companies with a US manufacturing presence, the overall impact remains unclear. This uncertainty is forcing companies like Apple to reassess their supply chain and manufacturing strategies, as evidenced by Apple’s recent $100 billion investment commitment to the US, including an ambitious American manufacturing program.

The decisions made in the next few months will be crucial. Businesses are expected to adapt, but the environment is changing rapidly. Geopolitical considerations are now as important as financial ones.

Frequently Asked Questions

  • What are the main challenges for businesses in the current trade environment?
    Unpredictable tariffs, fluctuating trade policies, and geopolitical risks.
  • What industries are most affected?
    Dairy, pharmaceuticals, and potentially semiconductors.
  • What can businesses do to mitigate risks?
    Monitor policy changes, diversify supply chains, and engage in scenario planning.

What are your thoughts on the future of global trade? Share your comments and insights below. Don’t forget to explore more articles about business and economics and subscribe to our newsletter for the latest updates!

August 8, 2025 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Dance Life: Empowering Youth Through Hip-Hop

    May 25, 2026
  • Rebuilding Faslane: Securing the Future of Royal Navy Submarines

    May 25, 2026
  • Wembanyama Leads Spurs Past Thunder to Tie Western Conference Finals 2-2

    May 25, 2026
  • NCDC Warns of High Ebola Importation Risk in Nigeria

    May 25, 2026
  • Samsung Galaxy S23 Users Upset Over Missing One UI 6.1.1 Feature

    May 25, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World